Adrenoleucodystrophy gene therapy - bluebird bio

Drug Profile

Adrenoleucodystrophy gene therapy - bluebird bio

Alternative Names: Lenti-D

Latest Information Update: 04 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genetix Pharmaceuticals; INSERM
  • Developer bluebird bio
  • Class Adrenoleucodystrophy gene therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Adrenoleucodystrophy

Most Recent Events

  • 26 Jun 2017 Efficacy data from the phase II/III Starbeam trial in Adrenoleukodystrophy released by bluebird bio
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Adrenoleucodystrophy in USA (Parenteral, Infusion)
  • 20 Apr 2016 Additional interim efficacy and adverse events data from phase II/III trial for Adrenoleukodystrophy presented at the 68th Annual Meeting of the American Academy of Neurology (AAN-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top